FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

Clifford J Bailey

doi:10.1111/dom.13669

FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

Clifford J Bailey

Research output: Contribution to journal › Letter, comment/opinion or interview › peer-review

68 Downloads (Pure)

Abstract

The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.

Original language	English
Pages (from-to)	1079-1080
Number of pages	2
Journal	Diabetes, Obesity and Metabolism
Volume	21
Issue number	5
Early online date	14 Feb 2019
DOIs	https://doi.org/10.1111/dom.13669
Publication status	Published - 1 May 2019

Bibliographical note

This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/dom.13669

FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later
This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Accepted author manuscript, 200 KB

Cite this

@article{f12748868684472cb11d9fc0e3ee9db3,

title = "FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later",

abstract = "The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.",

author = "Bailey, \{Clifford J\}",

note = "This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.",

year = "2019",

month = may,

day = "1",

doi = "10.1111/dom.13669",

language = "English",

volume = "21",

pages = "1079--1080",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

AU - Bailey, Clifford J

N1 - This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.

AB - The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.

UR - http://doi.wiley.com/10.1111/dom.13669

UR - https://www.scopus.com/pages/publications/85062947782

U2 - 10.1111/dom.13669

DO - 10.1111/dom.13669

M3 - Letter, comment/opinion or interview

SN - 1462-8902

VL - 21

SP - 1079

EP - 1080

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 5

ER -

FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this